Andrew R Blight1, Jane Hsieh2, Armin Curt3, James W Fawcett4, James D Guest5, Naomi Kleitman6, Shekar N Kurpad7, Brian K Kwon8, Daniel P Lammertse9, Norbert Weidner10, John D Steeves11. 1. Acorda Therapeutics, Inc., Ardsley, NY, USA. arborlight@gmail.com. 2. Wings for Life, Salzburg, Austria. 3. Spinal Cord Injury Center, University Hospital Balgrist, Zurich, Switzerland. 4. Cambridge University Centre for Brain Repair, Cambridge, UK. 5. Department of Neurosurgery, University of Miami, Miami, FL, USA. 6. Craig H. Neilsen Foundation, Encino, CA, USA. 7. Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 8. Vancouver Spine Surgery Institute and ICORD, University of British Columbia, Vancouver, Canada. 9. Craig Hospital, Englewood, CO, USA. 10. Spinal Cord Injury Center, Heidelberg University Hospital, Heidelberg, Germany. 11. ICORD, University of British Columbia, Vancouver, Canada.
Abstract
STUDY DESIGN: Narrative review by individuals experienced in the recruitment of participants to neurotherapeutic clinical trials in spinal cord injury (SCI). OBJECTIVES: To identify key problems of recruitment and explore potential approaches to overcoming them. METHODS: Published quantitative experience with recruitment of large-scale, experimental neurotherapeutic clinical studies targeting central nervous system and using primary outcome assessments validated for SCI over the last 3 decades was summarized. Based on this experience, potential approaches to improving recruitment were elicited from the authors. RESULTS: The rate of recruitment has varied between studies, depending on protocol design and other factors, but particularly inclusion/exclusion criteria. The recruitment rate also ranged over an order of magnitude between individual centers in a given study. In older multicenter studies, average recruitment rate was approximately one person per study center per month. More recent trials experienced lower rates of recruitment and potential reasons for this trend were examined. The current roles and potential of various stakeholder organizations in addressing problems of recruitment were explored. In addition, recent developments in methodology may help reduce the number of subjects required for well-powered studies. CONCLUSIONS: Several approaches are emerging to improve clinical trial design, efficacy outcome measures, and quantifiable surrogate markers, all of which should reduce the number of participants required for adequate statistical power. There is a growing sense of cooperation between various stakeholders but more should be done to bring together consumer and provider groups to improve recruitment and the effectiveness and relevance of neurotherapeutic clinical trials.
STUDY DESIGN: Narrative review by individuals experienced in the recruitment of participants to neurotherapeutic clinical trials in spinal cord injury (SCI). OBJECTIVES: To identify key problems of recruitment and explore potential approaches to overcoming them. METHODS: Published quantitative experience with recruitment of large-scale, experimental neurotherapeutic clinical studies targeting central nervous system and using primary outcome assessments validated for SCI over the last 3 decades was summarized. Based on this experience, potential approaches to improving recruitment were elicited from the authors. RESULTS: The rate of recruitment has varied between studies, depending on protocol design and other factors, but particularly inclusion/exclusion criteria. The recruitment rate also ranged over an order of magnitude between individual centers in a given study. In older multicenter studies, average recruitment rate was approximately one person per study center per month. More recent trials experienced lower rates of recruitment and potential reasons for this trend were examined. The current roles and potential of various stakeholder organizations in addressing problems of recruitment were explored. In addition, recent developments in methodology may help reduce the number of subjects required for well-powered studies. CONCLUSIONS: Several approaches are emerging to improve clinical trial design, efficacy outcome measures, and quantifiable surrogate markers, all of which should reduce the number of participants required for adequate statistical power. There is a growing sense of cooperation between various stakeholders but more should be done to bring together consumer and provider groups to improve recruitment and the effectiveness and relevance of neurotherapeutic clinical trials.
Authors: J D Steeves; D Lammertse; A Curt; J W Fawcett; M H Tuszynski; J F Ditunno; P H Ellaway; M G Fehlings; J D Guest; N Kleitman; P F Bartlett; A R Blight; V Dietz; B H Dobkin; R Grossman; D Short; M Nakamura; W P Coleman; M Gaviria; A Privat Journal: Spinal Cord Date: 2006-12-19 Impact factor: 2.772
Authors: D D Cardenas; J Ditunno; V Graziani; A B Jackson; D Lammertse; P Potter; M Sipski; R Cohen; A R Blight Journal: Spinal Cord Date: 2006-06-13 Impact factor: 2.772
Authors: Joseph P Minei; Timothy C Fabian; Danielle M Guffey; Craig D Newgard; Eileen M Bulger; Karen J Brasel; Jason L Sperry; Russell D MacDonald Journal: Ann Surg Date: 2014-09 Impact factor: 12.969
Authors: R Reed; M Mehra; S Kirshblum; D Maier; D Lammertse; A Blight; R Rupp; L Jones; R Abel; N Weidner; A Curt; J Steeves Journal: Spinal Cord Date: 2017-03-21 Impact factor: 2.772
Authors: Allan D Levi; Kim D Anderson; David O Okonkwo; Paul Park; Thomas N Bryce; Shekar N Kurpad; Bizhan Aarabi; Jane Hsieh; Katie Gant Journal: J Neurotrauma Date: 2018-10-19 Impact factor: 5.269
Authors: James D Guest; John D Steeves; M J Mulcahey; Linda A T Jones; Frank Rockhold; Rϋediger Rupp; John L K Kramer; Steven Kirshblum; Andrew Blight; Daniel Lammertse Journal: Spinal Cord Date: 2020-09-16 Impact factor: 2.772
Authors: Bastien Moineau; Andrea Brown; Louise Brisbois; Vera Zivanovic; Masae Miyatani; Naaz Kapadia; Jane T C Hsieh; Milos R Popovic Journal: J Spinal Cord Med Date: 2019-10 Impact factor: 1.985
Authors: Clara Farrehi; Carlotta Pazzi; Maclain Capron; Kim Anderson; Bonnie Richardson; Michael Stillman Journal: Spinal Cord Ser Cases Date: 2020-11-23
Authors: Brian K Kwon; Ona Bloom; Ina-Beate Wanner; Armin Curt; Jan M Schwab; James Fawcett; Kevin K Wang Journal: Spinal Cord Date: 2019-07-04 Impact factor: 2.772
Authors: Amy Janelle Minnema; A Mehta; Warren W Boling; Jan Schwab; J Marc Simard; H Francis Farhadi Journal: BMJ Open Date: 2019-10-10 Impact factor: 2.692